Results 1 to 10 of about 38,210 (254)

Adult T-cell leukaemia and lymphoma: report of two cases and a brief review of the literature [PDF]

open access: yes, 2002
Human T-cell lymphotropic virus type 1 (HTLV-1) can cause adult T-cell leukaemia/lymphoma (ATLL). Two patients originating from the Caribbean area with ATLL are described.
Pegels, J.G., Zaanen, H.C. van
core  

Screening donors for xenotransplantation: The potential for xenozoonoses [PDF]

open access: yes, 1994
Xenotransplantation is a potential solution to the current donor shortage for solid organ transplantation. The transmission of infectious agents from donor organs or bone marrow to the recipient is a well-recognized phenomenon following ...
Kahleen, B   +6 more
core   +1 more source

Distribution of adult T‐cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Although adult T‐cell leukaemia/lymphoma (ATL) has a higher burden in certain world regions, outcomes have not been directly compared across regions. We conducted a multicentre cohort study comparing the distribution of ATL subtypes and overall survival (OS) across 1090 adults (≥18 years) diagnosed with ATL during 2000–2023 in Japan (n = 366 ...
Bryan Valcarcel   +31 more
wiley   +1 more source

Dynamics of perinatal bovine leukemia virus infection [PDF]

open access: yes, 2014
BACKGROUND: Bovine leukemia virus (BLV) is highly endemic in many countries, including Argentina. As prevention of the spread from infected animals is of primary importance in breaking the cycle of BLV transmission, it is important to know the ...
Alvarez, Irene   +4 more
core   +3 more sources

Triple‐Mutated HSV‐1 Expressing Soluble B7‐1 Plus CTLA‐4 Blockade Suppresses Lymph Node Metastasis in Tongue Cancer

open access: yesCancer Science, EarlyView.
In murine tongue cancer models, T‐mB7‐1, a triple‐mutated oncolytic herpes simplex virus type 1 (HSV‐1) engineered to express soluble B7‐1, suppresses cervical lymph node metastasis and improves survival, addressing a major prognostic determinant in oral squamous cell carcinoma (OSCC).
Akinari Sugauchi   +11 more
wiley   +1 more source

A Case of Hypercalcemia due to Adult T-Cell Lymphoma

open access: yesCase Reports in Clinical Practice, 2018
Adult T-cell leukemia (ATL) is the only T-cell lymphoproliferative disease, known to be caused by a virus. While human T-lymphotropic virus type 1 (HTLV-1) is found to cause adult T-cell leukemia, other T-cell neoplastic diseases do not correlate with ...
Faeze Moghimpour-Bijani   +2 more
doaj  

Self-Flagellation as Possible Route of Human T-Cell Lymphotropic Virus Type-1 Transmission

open access: yesEmerging Infectious Diseases, 2019
We report human T-cell lymphotropic virus type 1 infection associated with self-flagellation in 10 UK residents. These persons were heterosexual men from Pakistan, India, and Iraq.
Alice R. Tang   +2 more
doaj   +1 more source

Alpha interferon restricts human T-lymphotropic virus type 1 and 2 De Novo infection through PKR activation [PDF]

open access: yes, 2013
International audienceType I interferon (IFN-I) inhibits the replication of different viruses. However, the effect of IFN-I on the human T-lymphotropic virus type 1 (HTLV-1) viral cycle is controversial.
Alais, Sandrine   +7 more
core   +4 more sources

Molecular targeting for treatment of human T-lymphotropic virus type 1 infection

open access: yesBiomedicine & Pharmacotherapy, 2019
Human T-cell lymphotropic virus type 1 (HTLV-1) infection is linked to adult T-cell leukemia-lymphoma (ATLL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and several other disorders. ATLL occurs in approximately 5% of the 15-20 million people infected by HTLV-1 in the world.
Arash Soltani   +7 more
openaire   +2 more sources

Re‐entry of donors deferred for false‐reactive screening tests in Canada: 10 years post implementation

open access: yesVox Sanguinis, EarlyView.
Abstract Background and Objectives Canadian Blood Services implemented a re‐entry programme in 2014. Donors deferred because of false‐reactive or indeterminate screening tests can provide a specimen for re‐entry testing 6 months after their initial test, and resume donating if they test negative for all infectious markers.
Chinchin Wang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy